基于EuBIVAS人群的脂蛋白(a)、载脂蛋白B-100和载脂蛋白A-I生物学变异模型分析性能规范
该研究在91名健康个体中连续10周采集血清,于6个欧洲实验室用Roche Cobas 8000 c702双份检测脂蛋白(a)、载脂蛋白B-100和载脂蛋白A-I的生物学变异。研究计算了分析性能规范与参考变化值,发现脂蛋白(a)的分析性能规范在各浓度五分位恒定且总体上低于基于现有数据的规范。
要点
- 脂蛋白(a)的个体内生物学变异在性别间存在显著差异。
- 脂蛋白(a)的分析性能规范在各浓度五分位恒定,且总体低于现有推荐。
- 载脂蛋白A-I和载脂蛋白B-100的分析性能规范与现有数据相似。
核心结论
- 研究数据证实了欧洲临床化学和实验室医学联合会数据库中脂蛋白(a)的生物学变异估计值。
- 研究结果强化了近期文章对旧版脂蛋白(a)分析性能规范推荐适用性的担忧。
- 鉴于脂蛋白(a)的异质性,需要更多符合BIVAC方案、纳入不同种族大量个体的研究。
研究设计与样本
- 研究从91名健康个体连续10周采集血清样本,在6个欧洲实验室使用Roche Cobas 8000 c702双份检测。
- 进行离群值、同质性和趋势分析,随后用CV-ANOVA确定生物学变异估计值及其95%置信区间。
- 基于生物学变异估计值计算分析性能规范和参考变化值,脂蛋白(a)的变异估计按归一化浓度五分位确定。
主要发现
- 脂蛋白(a)的个体内生物学变异在性别间存在显著差异。
- 载脂蛋白A-I和载脂蛋白B-100的个体内生物学变异在50岁以下与50岁以上女性间存在显著差异。
- 脂蛋白(a)的分析性能规范在各浓度五分位恒定,且总体低于基于目前发表数据的分析性能规范。
- 载脂蛋白A-I和载脂蛋白B-100的分析性能规范结果与现有数据相似。
局限性
- 脂蛋白(a)具有异质性,需要更多符合BIVAC方案、纳入不同种族大量个体的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With increased interest in lipoprotein(a) (Lp[a]) concentration as a target for risk reduction and growing clinical evidence of its impact on cardiovascular disease (CVD) risk, rigorous analytical performance specifications (APS) and accuracy targets for Lp(a) are required. We investigated the biological variation (BV) of Lp(a), and 2 other major biomarkers of CVD, apolipoprotein A-I (apoA-I) and apolipoprotein B-100 (apoB), in the European Biological Variation Study population. METHOD: Serum samples were drawn from 91 healthy individuals for 10 consecutive weeks at 6 European laboratories and analyzed in duplicate on a Roche Cobas 8000 c702. Outlier, homogeneity, and trend analysis were performed, followed by CV-ANOVA to determine BV estimates and their 95% CIs. These estimates were used to calculate APS and reference change values. For Lp(a), BV estimates were determined on normalized concentration quintiles. RESULTS: Within-subject BV estimates were significantly different between sexes for Lp(a) and between women aged <50 and >50 years for apoA-I and apoB. Lp(a) APS was constant across concentration quintiles and, overall, lower than APS based on currently published data, whereas results were similar for apoA-I and apoB. CONCLUSION: Using a fully Biological Variation Data Critical Appraisal Checklist (BIVAC)-compliant protocol, our study data confirm BV estimates of Lp(a) listed in the European Federation of Clinical Chemistry and Laboratory Medicine database and reinforce concerns expressed in recent articles regarding the suitability of older APS recommendations for Lp(a) measurements. Given the heterogeneity of Lp(a), more BIVAC-compliant studies on large numbers of individuals of different ethnic groups would be desirable.
引用
- Clouet-Foraison N, Marcovina SM, Guerra E, et al. Analytical Performance Specifications for Lipoprotein(a), Apolipoprotein B-100, and Apolipoprotein A-I Using the Biological Variation Model in the EuBIVAS Population. Clin Chem. 2020. PMID: 32353129. doi:10.1093/clinchem/hvaa054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。